Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study

Bone Marrow Transplantation volume 26, pages 23–29 (2000)Cite this article

Abstract

This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose levels expressed as mg/kg/day between days 1 and 30 (induction) and between days 31 and 100 (maintenance) were respectively: dose level I = 60/30 (n = 5); dose level II = 120/60 (n = 4); dose level III = 120/90 (n = 5) and dose level IV = 120/120 (n = 6). All patients showed engraftment: PMN ≥0.5 × 109/l at a median interval of 16, 21, 17, 15 days after BMT, and Plt ⩾30 × 109/l on days 19, 16, 17, 17 respectively. CMVAg-emia was seen in 10 patients at a median interval of 53 days post-BMT (range 33–89) with a median of 10 CMV antigen+ cells (range 1–16). There was a dose effect of foscarnet on CMVAg-emia: respectively 4/5 patients (80%), 2/4 (50%), 3/5 (60%) and 1/6 (18%) at dose levels I, II, III, IV (P = 0.1). CMV disease was seen in 3/9 (33%) at dose levels I, II and 0/11 at dose levels III, IV (P = 0.07). The median number of CMV antigen-positive cells at diagnosis of CMV infection was different: 13 in dose levels I–II and two in dose levels III–IV (P = 0.01). Increased creatininine was seen in 15 patients with a mean of 1.8 mg% (range 1.5–5.7) and was the cause of discontinuation in nine patients (45%). Renal toxicity was reversible in all nine patients. Overall actuarial TRM at 2 years was 31%: 47% for patients at dose levels I–II and 19% for patients at dose levels III–IV. In conclusion, foscarnet exhibits a dose-dependent prophylactic effect on CMVAg-emia, CMV disease and transplant-related mortality with acceptable and reversible renal toxicity. Bone Marrow Transplantation (2000) 26, 23–29.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Winston DJ, Gale RP . Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s Bone Marrow Transplant 1991 8: 7–11

    CAS  PubMed  Google Scholar 

  2. Weiner RS, Bortin N, Gale RP et al. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors Ann Intern Med 1986 104: 168–175

    Article  CAS  PubMed  Google Scholar 

  3. Meyers JD . Prevention and treatment of cytomegalovirus infection Ann Rev Med 1991 42: 179–187

    Article  CAS  PubMed  Google Scholar 

  4. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after bone marrow transplantation: risk factors for cytomegalovirus infection after human marrow transplantation New Engl J Med 1991 325: 1601–1607

    Article  CAS  PubMed  Google Scholar 

  5. Thé Th, van der Ploeg M, van der Berg J et al. Direct detection of cytomegalovirus in peripheral blood leukocytes – a review of the antigenemia assay and polymerase chain reaction Transplantation 1992 54: 193–198

    Article  PubMed  Google Scholar 

  6. Gerna G, Revello MG, Percivalle E et al. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins J Clin Microbiol 1990 28: 2681–2688

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Boeckh M, Bowden RA, Goodrich JM et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation Blood 1992 80: 1358–1364

    CAS  PubMed  Google Scholar 

  8. Bacigalupo A, Tedone E, Isaza A et al. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality Bone Marrow Transplant 1995 16: 155–161

    CAS  PubMed  Google Scholar 

  9. Kanda Y, Chiba S, Suzuki T et al. Time course analysis of semi-quantitative PCR and antigenemia assay for prevention of cytomegalovirus disease after bone marrow transplantation Br J Haematol 1998 100: 222–225

    Article  CAS  PubMed  Google Scholar 

  10. Gor D, Sabin C, Prentice HG et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease Bone Marrow Transplant 1998 21: 597–605

    Article  CAS  PubMed  Google Scholar 

  11. Matthes-Martin S, Aberle SW, Peters C et al. CMV-viraemia during allogeneic bone marrow transplantation in pediatric patients: association with survival and graft-versus-host disease Bone Marrow Transplant 1998 21: (S2) S53–S56

    PubMed  Google Scholar 

  12. Ljungman P, Oberg G, Aschan J et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients Bone Marrow Transplant 1996 18: 565–568

    CAS  PubMed  Google Scholar 

  13. Schmidt GM, Horak DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV study group New Engl J Med 1991 324: 1005–1011

    Article  CAS  PubMed  Google Scholar 

  14. Fajac A, Stephan F, Ibrahim A et al. Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipients Bone Marrow Transplant 1997 20: 581–585

    Article  CAS  PubMed  Google Scholar 

  15. Winston JD, Winston G, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 178–184

    Google Scholar 

  16. Goodrich J, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  17. Reusser P, Gambertoglio JG, Lilleby K et al. Phase I–II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients J Infect Dis 1992 166: 473–479

    Article  CAS  PubMed  Google Scholar 

  18. Bacigalupo A, Tedone E, van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections Bone Marrow Transplant 1994 13: 783–788

    CAS  PubMed  Google Scholar 

  19. Ringdén O, Lönnqvist B, Aschan J et al. Foscarnet prophylaxis in marrow transplant recipients Bone Marrow Transplant 1989 4: 713

    PubMed  Google Scholar 

  20. Öberg B . Antiviral effects of phosphonoformate (PFA, foscarnet sodium) Pharmacol Ther 1989 40: 1213–1285

    Article  Google Scholar 

  21. Aschan J, Ringdén O, Ljungman P et al. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients Scand J Infect Dis 1992 166: 473–479

    Article  Google Scholar 

  22. Bacigalupo A, Van Lint MT, Tedone E et al. Treatment of CMV infections in patients undergoing allogeneic bone marrow transplantation (BMT) with foscarnet. EBMT Congress, Stockholm 1992, poster abstract

  23. Drobyski WR, Knox KK, Carrigan DR et al. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation Transplantation 1991 52: 155–157

    Article  CAS  PubMed  Google Scholar 

  24. Deray G, Martinez F, Katlama C et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention Am J Nephrol 1989 9: 316–321

    Article  CAS  PubMed  Google Scholar 

  25. Lamparelli T, Van Lint MT, Gualandi F et al. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single centre experience Bone Marrow Transplant 1997 20: 1057–1067

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was also made possible by the support of Astra Arcus, Sodertaljie, Sweden. The study was also supported by Associazione Italiana Recerca contro il Cancro (AIRC) Milano grant to AB and Associazione Recerca Trapianto Midollo Osseo (ARITMO) Genova.

Author information

Authors and Affiliations

  1. Dipartimento di Ematologia, Ospedale San Martino, Genova, Italy

    S Bregante, S Bertilson, E Tedone, MT Van Lint, G Trespi, N Mordini, G Berisso, F Gualandi, T Lamparelli, O Figari, F Benvenuto, AM Raiola & A Bacigalupo

Authors
  1. S Bregante
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Bertilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Tedone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. MT Van Lint
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Trespi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Mordini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Berisso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Gualandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Lamparelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. O Figari
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Benvenuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. AM Raiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bregante, S., Bertilson, S., Tedone, E. et al. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 26, 23–29 (2000). https://doi.org/10.1038/sj.bmt.1702450

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702450

Keywords

This article is cited by

Search

Advanced search

Quick links